Novartis Itvisma Gains CHMP Boost for SMA Therapy
Basel, Switzerland | April 24, 2026 In a major breakthrough for rare disease treatment, Novartis has received a positive...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Basel, Switzerland | April 24, 2026 In a major breakthrough for rare disease treatment, Novartis has received a positive...
Pasadena, California | April 24, 2026 Arrowhead Pharmaceuticals has achieved a major regulatory milestone as the Committee for Medicinal...
PARIS, April 24, 2026 Sanofi has achieved a significant regulatory milestone as the European Medicines Agency’s Committee for Medicinal...
